Sphere Fluidics has won £1.6 million of a BIS £6.2 million Advanced Manufacturing Supply Chain Initative grant. The grant was led by the Centre for Process Innovation and other syndicate members included UCB, Lonza, Horizon Discovery and Alcyomics. “I am very pleased to win this grant”, said Dr Marian Rehak (R&D Director of Sphere Fluidics). “The syndicate aims to incorporate Sphere Fluidics’ Cyto-Mine platform into the biologics supply chain and revolutionise it.”. Other information can be found here.
The Discovery Fund recently made its second investment in a new University spin-out which is developing water droplets that serve as ‘miniature test tubes’.The picodroplet platform was developed by Professors Chris Abell and Wilhelm Huck of the Department of Chemistry. When the droplets are merged with others containing, for example, a specific chemical reagent, they effectively act as miniature reaction chambers that can be exposed to a unique set of experimental conditions. The technology has potential uses across a wide variety of fields, including drug discovery and algal biofuel development. Dr Frank Craig has been recruited as CEO, and the investment from the Discovery Fund will support the new company as it searches for its first customers and additional funding.
Sphere Fluidics has been nominated as a finalist in the East of England’s Business Weekly 2015 Life Sciences Innovation Award. “I am very pleased that our innovative, single cell analysis platform has been recognised in the biotech community” said Dr Rob Marchmont (Commercial Director). “AstraZeneca and MedImmune sponsored the award and Sphere Fluidics is a member of an exciting group of finalists”.
Sphere Fluidics’ CEO (Dr Frank F.Craig) will be pitching to a room of circa 50 investors at the Cambridge Enterprise Venture Partners dinner at Christ College, Cambridge (UK) on 17th March 2015. “I will be reviewing the significant commercial progress we are now experiencing plus outlining the Cyto-Mine program and the major new markets that we have identified to our current (and potentially new) investors. This marks the start of an exciting year of accelerated growth for Sphere Fluidics”.
Sphere Fluidics has submitted theTrademark for Cyto-Mine for filing in the US. Cyto-Mine is a novel single cell assay and monoclonality assurance system. “Cyto-Mine is creating a lot of excitement in the industry and the US is our biggest market. Thus, it is important for us to get IP protection in that region” said Dr Frank F. Craig (CEO). “We aim to have the trademark awarded late this year”.
Dr Rob Marchmont (Commercial Director) and Dr Frank F. Craig (CEO) will be attending Bio-Europe Spring 2015 in Paris (France) on March 9th-11th 2015. “We will be exhibiting at the UK Pavilion and also attending a number of biopartnering meetings with leading companies.” said Dr Marchmont. “Bio-Europe is a great conference and I look forward to meeting key companies and establishing new collaborations at the meeting.” said Dr Craig. Bio-Europe conference information can be found here.
Sphere Fluidics has been nominated by Real Business as one of the UK’s Top 50 Disruptive SMEs. This was part of the Everline Future 50 competition. Dr Rob Marchmont (Commercial Director) attended the awards ceremony and stated “It is great news that Cyto-Mine and our single cell analysis technology has been recognised by the broader UK business community as revolutionary”. Information on the award can be found here.